Evaluation of persistence and safety in extending of injection period of ustekinumab from every 8 to 12 weeks in patients with ulcerative colitis

Evaluation of persistence and safety in extending of injection period of ustekinumab from every 8 to 12 weeks in patients with ulcerative colitis - UC-EXTEND Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044286

Enrollment

Registered

2021-07-01

Start date

2021-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: UC patients with clinical remission treated by ustekinumab 90mg subcutaneous every 8 weeks

Exclusion criteria

Exclusion criteria: Patients of contraindication of ustekinumab Patients with pregnancy or lactating Patients without informed consent Patients with previous or ongoing malignancy Patients with colectomy Patients who is not appropriate for this study

Design outcomes

Primary

Measure	Time frame
Persistence rate until 1 year	—

Countries

Japan

Contacts

Public ContactShingo Kato

Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology

skato@saitama-med.ac.jp0492283564

Outcome results